Controlled Substances: Proposed Revised Aggregate Production Quotas for 2008, 37496-37498 [E8-14903]

Download as PDF 37496 Federal Register / Vol. 73, No. 127 / Tuesday, July 1, 2008 / Notices DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–307R] Controlled Substances: Proposed Revised Aggregate Production Quotas for 2008 Drug Enforcement Administration (DEA), Justice. ACTION: Notice of proposed revised 2008 aggregate production quotas. AGENCY: SUMMARY: This notice proposes revised 2008 aggregate production quotas for controlled substances in schedules I and II of the Controlled Substances Act (CSA). Written comments must be postmarked, and electronic comments must be sent, on or before July 31, 2008. ADDRESSES: To ensure proper handling of comments, please reference ‘‘Docket No. DEA–307R’’ on all written and electronic correspondence. Written comments sent via regular or express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 8701 Morrissette Drive, Springfield, VA 22152. Comments may be directly sent to DEA electronically by sending an electronic message to dea.diversion.policy@usdoj.gov. DATES: However, persons wishing to request a hearing should note that such requests must be written and manually signed; requests for a hearing will not be accepted via electronic means. DEA will accept attachments to electronic comments in Microsoft Word, WordPerfect, Adobe PDF, or Excel file formats only. DEA will not accept any file format other than those specifically listed here. FOR FURTHER INFORMATION CONTACT: Christine A. Sannerud, Ph.D., Chief, Drug and Chemical Evaluation Section, Drug Enforcement Administration, 8701 Morrissette Drive, Springfield, VA 22152, Telephone: (202) 307–7183. SUPPLEMENTARY INFORMATION: Section 306 of the CSA (21 U.S.C. 826) requires that the Attorney General establish aggregate production quotas for each basic class of controlled substance listed in schedules I and II. This responsibility has been delegated to the Administrator of the DEA by 28 CFR 0.100. The Administrator in turn, has redelegated this function to the Deputy Administrator, pursuant to 28 CFR 0.104. On August 24, 2007, a notice of proposed 2008 aggregate production quotas for certain controlled substances in schedules I and II was published in the Federal Register (72 FR 48683). This notice stipulated that the DEA would adjust the quotas in early 2008 as provided for in 21 CFR part 1303. The proposed revised 2008 aggregate production quotas represent those quantities of controlled substances in schedules I and II that may be produced in the United States in 2008 to provide adequate supplies of each substance for: the estimated medical, scientific, research and industrial needs of the United States; lawful export requirements; and the establishment and maintenance of reserve stocks. These quotas do not include imports of controlled substances for use in industrial processes. The proposed revisions are based on a review of 2007 year-end inventories, 2007 disposition data submitted by quota applicants, estimates of the medical needs of the United States, product development, and other information available to the DEA. Therefore, under the authority vested in the Attorney General by Section 306 of the CSA (21 U.S.C. 826), and delegated to the Administrator of the DEA by 28 CFR 0.100, and redelegated to the Deputy Administrator pursuant to 28 CFR 0.104, the Deputy Administrator hereby proposes the following revised 2008 aggregate production quotas for the following controlled substances, expressed in grams of anhydrous acid or base: Previously established initial 2008 quotas sroberts on PROD1PC70 with NOTICES Basic class—Schedule I 2,5–Dimethoxyamphetamine ........................................................................................................................... 2,5–Dimethoxy-4-ethylamphetamine (DOET) .................................................................................................. 2,5–Dimethoxy-4-(n)-propylthiophenethylamine (2C–T–7) .............................................................................. 3–Methylfentanyl .............................................................................................................................................. 3–Methylthiofentanyl ........................................................................................................................................ 3,4–Methylenedioxyamphetamine (MDA) ........................................................................................................ 3,4–Methylenedioxy-N-ethylamphetamine (MDEA) ......................................................................................... 3,4–Methylenedioxymethamphetamine (MDMA) ............................................................................................. 3,4,5–Trimethoxyamphetamine ....................................................................................................................... 4–Bromo-2,5-dimethoxyamphetamine (DOB) ................................................................................................. 4–Bromo-2,5-dimethoxyphenethylamine (2–CB) ............................................................................................. 4–Methoxyamphetamine .................................................................................................................................. 4–Methylaminorex ............................................................................................................................................ 4–Methyl-2,5-dimethoxyamphetamine (DOM) ................................................................................................. 5–Methoxy-3,4-methylenedioxyamphetamine ................................................................................................. 5–Methoxy-N,N-diisopropyltryptamine ............................................................................................................. Acetyl-alpha-methylfentanyl ............................................................................................................................. Acetyldihydrocodeine ....................................................................................................................................... Acetylmethadol ................................................................................................................................................ Allylprodine ...................................................................................................................................................... Alphacetylmethadol .......................................................................................................................................... Alpha-ethyltryptamine ...................................................................................................................................... Alphameprodine ............................................................................................................................................... Alphamethadol ................................................................................................................................................. Alpha-methylfentanyl ....................................................................................................................................... Alpha-methylthiofentanyl .................................................................................................................................. Alpha-methyltryptamine ................................................................................................................................... Aminorex .......................................................................................................................................................... Benzylmorphine ............................................................................................................................................... Betacetylmethadol ........................................................................................................................................... Beta-hydroxy-3-methylfentanyl ........................................................................................................................ Beta-hydroxyfentanyl ....................................................................................................................................... VerDate Aug<31>2005 21:01 Jun 30, 2008 Jkt 214001 PO 00000 Frm 00090 Fmt 4703 Sfmt 4703 E:\FR\FM\01JYN1.SGM 01JYN1 2 2 10 2 2 20 10 22 2 2 7 77 2 12 2 5 2 2 2 2 2 2 2 3 2 2 5 8 2 2 2 2 g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g Proposed revised 2008 quotas 2 2 10 2 2 20 10 22 2 2 7 77 2 12 2 5 2 2 2 2 2 2 2 3 2 2 5 8 2 2 2 2 g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g 37497 Federal Register / Vol. 73, No. 127 / Tuesday, July 1, 2008 / Notices Previously established initial 2008 quotas Basic class—Schedule I Betameprodine ................................................................................................................................................. Betamethadol ................................................................................................................................................... Betaprodine ...................................................................................................................................................... Bufotenine ........................................................................................................................................................ Cathinone ......................................................................................................................................................... Codeine-N-oxide .............................................................................................................................................. Diethyltryptamine ............................................................................................................................................. Difenoxin .......................................................................................................................................................... Dihydromorphine .............................................................................................................................................. Dimethyltryptamine .......................................................................................................................................... Gamma-hydroxybutyric acid ............................................................................................................................ Heroin .............................................................................................................................................................. Hydromorphinol ................................................................................................................................................ Hydroxypethidine ............................................................................................................................................. Ibogaine ........................................................................................................................................................... Lysergic acid diethylamide (LSD) .................................................................................................................... Marihuana ........................................................................................................................................................ Mescaline ......................................................................................................................................................... Methaqualone .................................................................................................................................................. Methcathinone ................................................................................................................................................. Methyldihydromorphine .................................................................................................................................... Morphine-N-oxide ............................................................................................................................................ N,N-Dimethylamphetamine .............................................................................................................................. N-Ethylamphetamine ....................................................................................................................................... N-Hydroxy-3,4-methylenedioxyamphetamine .................................................................................................. Noracymethadol ............................................................................................................................................... Norlevorphanol ................................................................................................................................................. Normethadone ................................................................................................................................................. Normorphine .................................................................................................................................................... Para-fluorofentanyl ........................................................................................................................................... Phenomorphan ................................................................................................................................................ Pholcodine ....................................................................................................................................................... Psilocybin ......................................................................................................................................................... Psilocyn ............................................................................................................................................................ Tetrahydrocannabinols .................................................................................................................................... Thiofentanyl ..................................................................................................................................................... Trimeperidine ................................................................................................................................................... 2 2 2 8 3 302 2 50 2,549,000 3 23,600,000 5 3,000 2 1 61 4,500,000 2 10 4 2 310 7 2 2 2 52 2 16 2 2 2 7 7 312,500 2 2 g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g Proposed revised 2008 quotas 2 2 2 8 3 302 2 50 2,549,000 3 21,940,000 5 3,000 2 1 61 4,500,000 2 10 4 2 310 7 2 2 2 52 2 16 2 2 2 7 7 312,500 2 2 g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g sroberts on PROD1PC70 with NOTICES Basic class—Schedule II Previously established initial 2008 quotas Proposed revised 2008 quotas 1–Phenylcyclohexylamine ................................................................................................................................ Alfentanil .......................................................................................................................................................... Alphaprodine .................................................................................................................................................... Amobarbital ...................................................................................................................................................... Amphetamine (for sale) ................................................................................................................................... Amphetamine (for conversion) ........................................................................................................................ Cocaine ............................................................................................................................................................ Codeine (for sale) ............................................................................................................................................ Codeine (for conversion) ................................................................................................................................. Dextropropoxyphene ........................................................................................................................................ Dihydrocodeine ................................................................................................................................................ Diphenoxylate .................................................................................................................................................. Ecgonine .......................................................................................................................................................... Ethylmorphine .................................................................................................................................................. Fentanyl ........................................................................................................................................................... Glutethimide ..................................................................................................................................................... Hydrocodone (for sale) .................................................................................................................................... Hydrocodone (for conversion) ......................................................................................................................... Hydromorphone ............................................................................................................................................... Isomethadone .................................................................................................................................................. Levo-alphacetylmethadol (LAAM) .................................................................................................................... Levomethorphan .............................................................................................................................................. Levorphanol ..................................................................................................................................................... Lisdexamfetamine ............................................................................................................................................ Meperidine ....................................................................................................................................................... Metazocine ....................................................................................................................................................... Methadone (for sale) ....................................................................................................................................... Methadone Intermediate .................................................................................................................................. Methamphetamine ........................................................................................................................................... 2 8,000 2 3 17,000,000 5,000,000 286,000 39,605,000 59,000,000 106,000,000 1,200,000 828,000 83,000 2 1,428,000 2 45,200,000 1,500,000 3,300,000 2 3 5 10,000 6,200,000 9,753,000 1 25,000,000 26,000,000 3,130,000 2 8,000 2 3 17,000,000 5,000,000 247,000 39,605,000 59,000,000 106,000,000 1,200,000 680,000 83,000 2 1,428,000 2 42,000,000 1,500,000 3,300,000 2 3 5 10,000 6,200,000 8,600,000 1 25,000,000 26,000,000 3,130,000 VerDate Aug<31>2005 21:01 Jun 30, 2008 Jkt 214001 PO 00000 Frm 00091 Fmt 4703 Sfmt 4703 E:\FR\FM\01JYN1.SGM 01JYN1 g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g 37498 Federal Register / Vol. 73, No. 127 / Tuesday, July 1, 2008 / Notices Previously established initial 2008 quotas Basic class—Schedule II Proposed revised 2008 quotas [680,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 2,405,000 grams for methamphetamine mostly for conversion to a schedule III product; and 45,000 grams for methamphetamine (for sale)] Methylphenidate ............................................................................................................................................... Morphine (for sale) .......................................................................................................................................... Morphine (for conversion) ................................................................................................................................ Nabilone ........................................................................................................................................................... Noroxymorphone (for sale) .............................................................................................................................. Noroxymorphone (for conversion) ................................................................................................................... Oripavine1 ........................................................................................................................................................ Opium .............................................................................................................................................................. Oxycodone (for sale) ....................................................................................................................................... Oxycodone (for conversion) ............................................................................................................................ Oxymorphone .................................................................................................................................................. Oxymorphone (for conversion) ........................................................................................................................ Pentobarbital .................................................................................................................................................... Phencyclidine ................................................................................................................................................... Phenmetrazine ................................................................................................................................................. Racemethorphan ............................................................................................................................................. Remifentanil ..................................................................................................................................................... Secobarbital ..................................................................................................................................................... Sufentanil ......................................................................................................................................................... Thebaine .......................................................................................................................................................... 50,000,000 35,000,000 100,000,000 3,002 10,000 8,000,000 0 1,400,000 70,000,000 4,820,000 2,400,000 11,000,000 35,200,000 2,021 2 2 3,000 2 10,300 126,000,000 g g g g g g g g g g g g g g g g g g g g 50,000,000 35,000,000 100,000,000 3,002 10,000 8,000,000 15,000,000 1,400,000 70,000,000 4,820,000 2,000,000 11,000,000 28,000,000 2,021 2 2 410 2 10,300 126,000,000 g g g g g g g g g g g g g g g g g g g g 1 On December 10, 2007, the Drug Enforcement Administration published a final rule establishing a new basic class: Oripavine (72 FR 69618). Prior to the final rule, oripavine was considered a thebaine derivative and hence, was included under the thebaine basic class. The Deputy Administrator further proposes that aggregate production quotas for all other schedules I and II controlled substances included in 21 CFR 1308.11 and 1308.12 remain at zero. All interested persons are invited to submit their comments in writing or electronically regarding this proposal following the procedures in the ADDRESSES section of this document. A person may object to or comment on the proposal relating to any of the abovementioned substances without filing comments or objections regarding the others. If a person believes that one or more of these issues warrant a hearing, the individual should so state and summarize the reasons for this belief. Persons wishing to request a hearing should note that such requests must be written and manually signed; requests for a hearing will not be accepted via electronic means. In the event that comments or objections to this proposal raise one or more issues which the Deputy Administrator finds warrant a hearing, the Deputy Administrator shall order a public hearing by notice in the Federal Register, summarizing the issues to be heard and setting the time for the hearing as per 21 CFR 1303.13(c). sroberts on PROD1PC70 with NOTICES Regulatory Certifications Regulatory Flexibility Act The Deputy Administrator hereby certifies that this action will not have a significant economic impact upon small entities whose interests must be VerDate Aug<31>2005 21:01 Jun 30, 2008 Jkt 214001 considered under the Regulatory Flexibility Act, 5 U.S.C. 601–612. The establishment of aggregate production quotas for schedules I and II controlled substances is mandated by law and by international treaty obligations. The quotas are necessary to provide for the estimated medical, scientific, research and industrial needs of the United States, for lawful export requirements, and the establishment and maintenance of reserve stocks. While aggregate production quotas are of primary importance to large manufacturers, their impact upon small entities is neither negative nor beneficial. Accordingly, the Deputy Administrator has determined that this action does not require a regulatory flexibility analysis. Executive Order 12988 Executive Order 12866 This action is not a major rule as defined by Section 804 of the Small Business Regulatory Enforcement Fairness Act of 1996 (Congressional Review Act). This action will not result in an annual effect on the economy of $100,000,000 or more; a major increase in costs or prices; or significant adverse effects on competition, employment, investment, productivity, innovation, or on the ability of United States-based companies to compete with foreignbased companies in domestic and export markets. The Office of Management and Budget has determined that notices of aggregate production quotas are not subject to centralized review under Executive Order 12866. Executive Order 13132 This action does not preempt or modify any provision of state law; nor does it impose enforcement responsibilities on any state; nor does it diminish the power of any state to enforce its own laws. Accordingly, this action does not have federalism implications warranting the application of Executive Order 13132. PO 00000 This action meets the applicable standards set forth in Sections 3(a) and 3(b)(2) of Executive Order 12988 Civil Justice Reform. Unfunded Mandates Reform Act of 1995 This action will not result in the expenditure by state, local, and tribal governments, in the aggregate, or by the private sector, of $120,000,000 or more (adjusted for inflation) in any one year, and will not significantly or uniquely affect small governments. Therefore, no actions were deemed necessary under the provisions of the Unfunded Mandates Reform Act of 1995. Congressional Review Act Dated: June 6, 2008. Michele M. Leonhart, Deputy Administrator. [FR Doc. E8–14903 Filed 6–30–08; 8:45 am] BILLING CODE 4410–09–P Frm 00092 Fmt 4703 Sfmt 4703 E:\FR\FM\01JYN1.SGM 01JYN1

Agencies

[Federal Register Volume 73, Number 127 (Tuesday, July 1, 2008)]
[Notices]
[Pages 37496-37498]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-14903]



[[Page 37496]]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-307R]


Controlled Substances: Proposed Revised Aggregate Production 
Quotas for 2008

AGENCY: Drug Enforcement Administration (DEA), Justice.

ACTION: Notice of proposed revised 2008 aggregate production quotas.

-----------------------------------------------------------------------

SUMMARY: This notice proposes revised 2008 aggregate production quotas 
for controlled substances in schedules I and II of the Controlled 
Substances Act (CSA).

DATES: Written comments must be postmarked, and electronic comments 
must be sent, on or before July 31, 2008.

ADDRESSES: To ensure proper handling of comments, please reference 
``Docket No. DEA-307R'' on all written and electronic correspondence. 
Written comments sent via regular or express mail should be sent to DEA 
Headquarters, Attention: DEA Federal Register Representative/ODL, 8701 
Morrissette Drive, Springfield, VA 22152. Comments may be directly sent 
to DEA electronically by sending an electronic message to 
dea.diversion.policy@usdoj.gov. However, persons wishing to request a 
hearing should note that such requests must be written and manually 
signed; requests for a hearing will not be accepted via electronic 
means. DEA will accept attachments to electronic comments in Microsoft 
Word, WordPerfect, Adobe PDF, or Excel file formats only. DEA will not 
accept any file format other than those specifically listed here.

FOR FURTHER INFORMATION CONTACT: Christine A. Sannerud, Ph.D., Chief, 
Drug and Chemical Evaluation Section, Drug Enforcement Administration, 
8701 Morrissette Drive, Springfield, VA 22152, Telephone: (202) 307-
7183.

SUPPLEMENTARY INFORMATION: Section 306 of the CSA (21 U.S.C. 826) 
requires that the Attorney General establish aggregate production 
quotas for each basic class of controlled substance listed in schedules 
I and II. This responsibility has been delegated to the Administrator 
of the DEA by 28 CFR 0.100. The Administrator in turn, has redelegated 
this function to the Deputy Administrator, pursuant to 28 CFR 0.104.
    On August 24, 2007, a notice of proposed 2008 aggregate production 
quotas for certain controlled substances in schedules I and II was 
published in the Federal Register (72 FR 48683). This notice stipulated 
that the DEA would adjust the quotas in early 2008 as provided for in 
21 CFR part 1303.
    The proposed revised 2008 aggregate production quotas represent 
those quantities of controlled substances in schedules I and II that 
may be produced in the United States in 2008 to provide adequate 
supplies of each substance for: the estimated medical, scientific, 
research and industrial needs of the United States; lawful export 
requirements; and the establishment and maintenance of reserve stocks. 
These quotas do not include imports of controlled substances for use in 
industrial processes.
    The proposed revisions are based on a review of 2007 year-end 
inventories, 2007 disposition data submitted by quota applicants, 
estimates of the medical needs of the United States, product 
development, and other information available to the DEA.
    Therefore, under the authority vested in the Attorney General by 
Section 306 of the CSA (21 U.S.C. 826), and delegated to the 
Administrator of the DEA by 28 CFR 0.100, and redelegated to the Deputy 
Administrator pursuant to 28 CFR 0.104, the Deputy Administrator hereby 
proposes the following revised 2008 aggregate production quotas for the 
following controlled substances, expressed in grams of anhydrous acid 
or base:

----------------------------------------------------------------------------------------------------------------
                                                                                 Previously
                                                                                 established    Proposed revised
                           Basic class--Schedule I                              initial 2008       2008 quotas
                                                                                   quotas
----------------------------------------------------------------------------------------------------------------
2,5-Dimethoxyamphetamine....................................................               2 g               2 g
2,5-Dimethoxy-4-ethylamphetamine (DOET).....................................               2 g               2 g
2,5-Dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7).......................              10 g              10 g
3-Methylfentanyl............................................................               2 g               2 g
3-Methylthiofentanyl........................................................               2 g               2 g
3,4-Methylenedioxyamphetamine (MDA).........................................              20 g              20 g
3,4-Methylenedioxy-N-ethylamphetamine (MDEA)................................              10 g              10 g
3,4-Methylenedioxymethamphetamine (MDMA)....................................              22 g              22 g
3,4,5-Trimethoxyamphetamine.................................................               2 g               2 g
4-Bromo-2,5-dimethoxyamphetamine (DOB)......................................               2 g               2 g
4-Bromo-2,5-dimethoxyphenethylamine (2-CB)..................................               7 g               7 g
4-Methoxyamphetamine........................................................              77 g              77 g
4-Methylaminorex............................................................               2 g               2 g
4-Methyl-2,5-dimethoxyamphetamine (DOM).....................................              12 g              12 g
5-Methoxy-3,4-methylenedioxyamphetamine.....................................               2 g               2 g
5-Methoxy-N,N-diisopropyltryptamine.........................................               5 g               5 g
Acetyl-alpha-methylfentanyl.................................................               2 g               2 g
Acetyldihydrocodeine........................................................               2 g               2 g
Acetylmethadol..............................................................               2 g               2 g
Allylprodine................................................................               2 g               2 g
Alphacetylmethadol..........................................................               2 g               2 g
Alpha-ethyltryptamine.......................................................               2 g               2 g
Alphameprodine..............................................................               2 g               2 g
Alphamethadol...............................................................               3 g               3 g
Alpha-methylfentanyl........................................................               2 g               2 g
Alpha-methylthiofentanyl....................................................               2 g               2 g
Alpha-methyltryptamine......................................................               5 g               5 g
Aminorex....................................................................               8 g               8 g
Benzylmorphine..............................................................               2 g               2 g
Betacetylmethadol...........................................................               2 g               2 g
Beta-hydroxy-3-methylfentanyl...............................................               2 g               2 g
Beta-hydroxyfentanyl........................................................               2 g               2 g

[[Page 37497]]

 
Betameprodine...............................................................               2 g               2 g
Betamethadol................................................................               2 g               2 g
Betaprodine.................................................................               2 g               2 g
Bufotenine..................................................................               8 g               8 g
Cathinone...................................................................               3 g               3 g
Codeine-N-oxide.............................................................             302 g             302 g
Diethyltryptamine...........................................................               2 g               2 g
Difenoxin...................................................................              50 g              50 g
Dihydromorphine.............................................................       2,549,000 g       2,549,000 g
Dimethyltryptamine..........................................................               3 g               3 g
Gamma-hydroxybutyric acid...................................................      23,600,000 g      21,940,000 g
Heroin......................................................................               5 g               5 g
Hydromorphinol..............................................................           3,000 g           3,000 g
Hydroxypethidine............................................................               2 g               2 g
Ibogaine....................................................................               1 g               1 g
Lysergic acid diethylamide (LSD)............................................              61 g              61 g
Marihuana...................................................................       4,500,000 g       4,500,000 g
Mescaline...................................................................               2 g               2 g
Methaqualone................................................................              10 g              10 g
Methcathinone...............................................................               4 g               4 g
Methyldihydromorphine.......................................................               2 g               2 g
Morphine-N-oxide............................................................             310 g             310 g
N,N-Dimethylamphetamine.....................................................               7 g               7 g
N-Ethylamphetamine..........................................................               2 g               2 g
N-Hydroxy-3,4-methylenedioxyamphetamine.....................................               2 g               2 g
Noracymethadol..............................................................               2 g               2 g
Norlevorphanol..............................................................              52 g              52 g
Normethadone................................................................               2 g               2 g
Normorphine.................................................................              16 g              16 g
Para-fluorofentanyl.........................................................               2 g               2 g
Phenomorphan................................................................               2 g               2 g
Pholcodine..................................................................               2 g               2 g
Psilocybin..................................................................               7 g               7 g
Psilocyn....................................................................               7 g               7 g
Tetrahydrocannabinols.......................................................         312,500 g         312,500 g
Thiofentanyl................................................................               2 g               2 g
Trimeperidine...............................................................               2 g               2 g
----------------------------------------------------------------------------------------------------------------


----------------------------------------------------------------------------------------------------------------
                                                                                 Previously
                                                                                 established    Proposed revised
                          Basic class--Schedule II                              initial 2008       2008 quotas
                                                                                   quotas
----------------------------------------------------------------------------------------------------------------
1-Phenylcyclohexylamine.....................................................               2 g               2 g
Alfentanil..................................................................           8,000 g           8,000 g
Alphaprodine................................................................               2 g               2 g
Amobarbital.................................................................               3 g               3 g
Amphetamine (for sale)......................................................      17,000,000 g      17,000,000 g
Amphetamine (for conversion)................................................       5,000,000 g       5,000,000 g
Cocaine.....................................................................         286,000 g         247,000 g
Codeine (for sale)..........................................................      39,605,000 g      39,605,000 g
Codeine (for conversion)....................................................      59,000,000 g      59,000,000 g
Dextropropoxyphene..........................................................     106,000,000 g     106,000,000 g
Dihydrocodeine..............................................................       1,200,000 g       1,200,000 g
Diphenoxylate...............................................................         828,000 g         680,000 g
Ecgonine....................................................................          83,000 g          83,000 g
Ethylmorphine...............................................................               2 g               2 g
Fentanyl....................................................................       1,428,000 g       1,428,000 g
Glutethimide................................................................               2 g               2 g
Hydrocodone (for sale)......................................................      45,200,000 g      42,000,000 g
Hydrocodone (for conversion)................................................       1,500,000 g       1,500,000 g
Hydromorphone...............................................................       3,300,000 g       3,300,000 g
Isomethadone................................................................               2 g               2 g
Levo-alphacetylmethadol (LAAM)..............................................               3 g               3 g
Levomethorphan..............................................................               5 g               5 g
Levorphanol.................................................................          10,000 g          10,000 g
Lisdexamfetamine............................................................       6,200,000 g       6,200,000 g
Meperidine..................................................................       9,753,000 g       8,600,000 g
Metazocine..................................................................               1 g               1 g
Methadone (for sale)........................................................      25,000,000 g      25,000,000 g
Methadone Intermediate......................................................      26,000,000 g      26,000,000 g
Methamphetamine.............................................................       3,130,000 g       3,130,000 g

[[Page 37498]]

 
  [680,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 2,405,000 grams
 for methamphetamine mostly for conversion to a schedule III product; and 45,000 grams for methamphetamine (for
                                                     sale)]
----------------------------------------------------------------------------------------------------------------
Methylphenidate.............................................................      50,000,000 g      50,000,000 g
Morphine (for sale).........................................................      35,000,000 g      35,000,000 g
Morphine (for conversion)...................................................     100,000,000 g     100,000,000 g
Nabilone....................................................................           3,002 g           3,002 g
Noroxymorphone (for sale)...................................................          10,000 g          10,000 g
Noroxymorphone (for conversion).............................................       8,000,000 g       8,000,000 g
Oripavine\1\................................................................               0 g      15,000,000 g
Opium.......................................................................       1,400,000 g       1,400,000 g
Oxycodone (for sale)........................................................      70,000,000 g      70,000,000 g
Oxycodone (for conversion)..................................................       4,820,000 g       4,820,000 g
Oxymorphone.................................................................       2,400,000 g       2,000,000 g
Oxymorphone (for conversion)................................................      11,000,000 g      11,000,000 g
Pentobarbital...............................................................      35,200,000 g      28,000,000 g
Phencyclidine...............................................................           2,021 g           2,021 g
Phenmetrazine...............................................................               2 g               2 g
Racemethorphan..............................................................               2 g               2 g
Remifentanil................................................................           3,000 g             410 g
Secobarbital................................................................               2 g               2 g
Sufentanil..................................................................          10,300 g          10,300 g
Thebaine....................................................................     126,000,000 g     126,000,000 g
----------------------------------------------------------------------------------------------------------------
\1\ On December 10, 2007, the Drug Enforcement Administration published a final rule establishing a new basic
  class: Oripavine (72 FR 69618). Prior to the final rule, oripavine was considered a thebaine derivative and
  hence, was included under the thebaine basic class.

    The Deputy Administrator further proposes that aggregate production 
quotas for all other schedules I and II controlled substances included 
in 21 CFR 1308.11 and 1308.12 remain at zero.
    All interested persons are invited to submit their comments in 
writing or electronically regarding this proposal following the 
procedures in the ADDRESSES section of this document. A person may 
object to or comment on the proposal relating to any of the above-
mentioned substances without filing comments or objections regarding 
the others. If a person believes that one or more of these issues 
warrant a hearing, the individual should so state and summarize the 
reasons for this belief. Persons wishing to request a hearing should 
note that such requests must be written and manually signed; requests 
for a hearing will not be accepted via electronic means.
    In the event that comments or objections to this proposal raise one 
or more issues which the Deputy Administrator finds warrant a hearing, 
the Deputy Administrator shall order a public hearing by notice in the 
Federal Register, summarizing the issues to be heard and setting the 
time for the hearing as per 21 CFR 1303.13(c).

Regulatory Certifications

Regulatory Flexibility Act

    The Deputy Administrator hereby certifies that this action will not 
have a significant economic impact upon small entities whose interests 
must be considered under the Regulatory Flexibility Act, 5 U.S.C. 601-
612. The establishment of aggregate production quotas for schedules I 
and II controlled substances is mandated by law and by international 
treaty obligations. The quotas are necessary to provide for the 
estimated medical, scientific, research and industrial needs of the 
United States, for lawful export requirements, and the establishment 
and maintenance of reserve stocks. While aggregate production quotas 
are of primary importance to large manufacturers, their impact upon 
small entities is neither negative nor beneficial. Accordingly, the 
Deputy Administrator has determined that this action does not require a 
regulatory flexibility analysis.

Executive Order 12866

    The Office of Management and Budget has determined that notices of 
aggregate production quotas are not subject to centralized review under 
Executive Order 12866.

Executive Order 13132

    This action does not preempt or modify any provision of state law; 
nor does it impose enforcement responsibilities on any state; nor does 
it diminish the power of any state to enforce its own laws. 
Accordingly, this action does not have federalism implications 
warranting the application of Executive Order 13132.

Executive Order 12988

    This action meets the applicable standards set forth in Sections 
3(a) and 3(b)(2) of Executive Order 12988 Civil Justice Reform.

Unfunded Mandates Reform Act of 1995

    This action will not result in the expenditure by state, local, and 
tribal governments, in the aggregate, or by the private sector, of 
$120,000,000 or more (adjusted for inflation) in any one year, and will 
not significantly or uniquely affect small governments. Therefore, no 
actions were deemed necessary under the provisions of the Unfunded 
Mandates Reform Act of 1995.

Congressional Review Act

    This action is not a major rule as defined by Section 804 of the 
Small Business Regulatory Enforcement Fairness Act of 1996 
(Congressional Review Act). This action will not result in an annual 
effect on the economy of $100,000,000 or more; a major increase in 
costs or prices; or significant adverse effects on competition, 
employment, investment, productivity, innovation, or on the ability of 
United States-based companies to compete with foreign-based companies 
in domestic and export markets.

    Dated: June 6, 2008.
Michele M. Leonhart,
Deputy Administrator.
[FR Doc. E8-14903 Filed 6-30-08; 8:45 am]
BILLING CODE 4410-09-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.